3/5
05:46 pm
upb
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight [Yahoo! Finance]
Low
Report
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight [Yahoo! Finance]
3/1
10:03 am
upb
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting [Yahoo! Finance]
Neutral
Report
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting [Yahoo! Finance]
3/1
09:45 am
upb
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Neutral
Report
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
2/26
07:32 am
upb
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 [Yahoo! Finance]
Low
Report
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 [Yahoo! Finance]
2/26
07:00 am
upb
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Low
Report
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
2/25
07:00 am
upb
Upstream Bio to Participate in Upcoming March Investor Conferences
Medium
Report
Upstream Bio to Participate in Upcoming March Investor Conferences
2/12
02:02 pm
upb
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
Low
Report
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]
2/11
06:00 am
upb
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
High
Report
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
2/10
06:52 pm
upb
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]
High
Report
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma [Yahoo! Finance]
2/10
06:00 pm
upb
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
High
Report
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
1/8
12:20 pm
upb
Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]
Low
Report
Upstream Bio: Fully Priced After Recent Rally [Seeking Alpha]
1/5
07:00 am
upb
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/19
05:59 am
upb
Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Medium
Report
Upstream Bio (NASDAQ:UPB) was upgraded by analysts at Mizuho to a "strong-buy" rating.
12/17
07:01 pm
upb
Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.
Medium
Report
Upstream Bio (NASDAQ:UPB) was given a new $51.00 price target on by analysts at Mizuho.